Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
| ▸ | PTPRE | P23469 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305505 | 0.83 | ALDH1A1 (0.63) | ALDH1A1TP53ANO1PTPRCPTPN2 | |
| SCHEMBL1164647 | 0.83 | TSHR (0.42) | ALDH1A1TP53PTPRCPTPN2PTPN1 | |
| SCHEMBL31364369 | 0.83 | ALDH1A1 (0.63) | ALDH1A1TP53ANO1PTPRCPTPN2 | |
| SCHEMBL21921083 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TP53ANO1ABL1BCR | |
| SCHEMBL1786179 | 0.81 | ALDH1A1 (0.50) | ALDH1A1TP53ANO1ABL1BCR | |
| SCHEMBL27994220 | 0.81 | ALDH1A1 (0.61) | ALDH1A1TP53ANO1PTPRCPTPN2 | |
| SCHEMBL15471933 | 0.80 | ALDH1A1 (0.68) | ALDH1A1ANO1KDM4ENPC1POLB | |
| SCHEMBL27454155 | 0.80 | PTPN2 (0.39) | ALDH1A1PTPRCPTPN2PTPN1PTPRA | |
| SCHEMBL23242473 | 0.78 | AR (0.47) | ALDH1A1PTPRCPTPN2PTPN1PTPRA | |
| SCHEMBL699001 | 0.77 | ALDH1A1 (0.68) | ALDH1A1TP53KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110872216-A | Method and device for producing (2-chloro-5-iodophenyl) -4-fluorobenzyl ketone by reaction separation coupling | 南京恒道医药科技有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-116332882-B | Synthesis process of key intermediate of englitz | 江苏阿尔法集团福瑞药业(宿迁)有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-117964583-A | Preparation method of Engliclazide chiral intermediate | 江苏阿尔法药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117946039-A | Chiral synthesis process of englitz intermediate | 江苏阿尔法药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117683003-A | New process for synthesizing englitjing intermediate | 江苏阿尔法集团福瑞药业(宿迁)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-116332882-A | Synthesis process of key intermediate of englitz | 江苏福瑞康泰药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-16 | — | — | US | disclosed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080081928-A1 | reacting 2-chloro-5-iodo-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide with allyl alcohol in the presence of a palladium catalyst and a tertiary amine base, to form 2-chloro-5-(3-oxopropyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; chemical intermediates for drugs | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008030160-A1 | PROCESS FOR PREPARING N-METHYLADAMANTYL DERIVATIVES BY A PALLADIUM CATALYSED COUPLING REACTION FOLLOWED BY REDUCTIVE AMINATION | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | WO | disclosed |
| CN-1161336-C | Quinoline carboxamides as antiviral agents | �������Ŷ���Լ��������˾ | 2004-08-11 | — | — | CN | disclosed |
| CN-1333753-A | Quinoline carboxamides as antiviral agents | UPJOHN CO (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388016-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 1242/4885TP53 4884/4885ANO1 817/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | ALDH1A1 4404/4885TP53 1392/4885ANO1 4662/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | ALDH1A1 3006/4885TP53 628/4885ANO1 1134/4885 |
| US-20210388015-A1 | GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, UGGT1 | ALDH1A1 1242/4885TP53 4884/4885ANO1 817/4885 |
| US-20080081928-A1 | reacting 2-chloro-5-iodo-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide with allyl alcohol in the presence of a palladium catalyst and a tertiary amine base, to form 2-chloro-5-(3-oxopropyl)-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; chemical intermediates for drugs | ADH1A, ADH1C, ADH5 | ALDH1A1 4/4885TP53 4421/4885ANO1 349/4885 |
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | ALDH1A1 1202/4885TP53 4619/4885ANO1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.